Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-1110-07 Phase IIa trial in major depressive disorder
jRCT2031240577Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing ONO-1110 with Placebo (2 arms). Primary endpoint: Change in HAM-D17 total score from baseline. Started Jan 2025; status: completed.
02
Drugs
ONO-1110
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2031240577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240577.